Suggested Channels
52 Week Highs Dividend Stocks


The Heat Map shows these symbols by color. Each symbol can be clicked to scroll to the symbol details.

Below is a clickable Heat Map of the 1 symbols on this page. The percent change is based on Monday's prices. Each symbol is a hyperlink or shortcut to more information.

BIIB 2.59%

BIIB $282.27 7.12 (2.59%)
Profile NASDAQ: BIIB $51 Billion Large-Cap. Show More

BIIB Profile

Market Cap 51 Billion
BIIB Description

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Tysabri and Tecfidera. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

Visit Website

BIIB Earnings

EPS 8.40 P/E Ratio 10.77
Previous Tue, Jul 23, 2019
Latest Tue, Oct 22, 2019 (27 days ago) Price +26.29%

BIIB Dividend

Yield --
Ex-Date --
Pay Date --
History --

BIIB Charts

1 Year
Sep 4, 2019
Jan 23, 2019

Symbol Price Day Ξ” YTD Ξ”
BIIB $282.27 2.59% -7.36%


Symbol Surfing

How can we make Symbol Surfing better?


©2019 Symbol Surfing All Rights Reserved.

Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

Cookies Policy | Terms Of Service | Privacy Policy